Role of T cells in cancer immunotherapy: Opportunities and challenges

Cancer pathogenesis and therapy Pub Date : 2023-04-01 DOI:10.1016/j.cpt.2022.12.002

Hossain Ahmed , Aar Rafi Mahmud , Mohd. Faijanur - Rob - Siddiquee , Asif Shahriar , Partha Biswas , Md. Ebrahim Khalil Shimul , Shahlaa Zernaz Ahmed , Tanzila Ismail Ema , Nova Rahman , Md. Arif Khan , Md. Furkanur Rahaman Mizan , Talha Bin Emran

{"title":"Role of T cells in cancer immunotherapy: Opportunities and challenges","authors":"Hossain Ahmed , Aar Rafi Mahmud , Mohd. Faijanur - Rob - Siddiquee , Asif Shahriar , Partha Biswas , Md. Ebrahim Khalil Shimul , Shahlaa Zernaz Ahmed , Tanzila Ismail Ema , Nova Rahman , Md. Arif Khan , Md. Furkanur Rahaman Mizan , Talha Bin Emran","doi":"10.1016/j.cpt.2022.12.002","DOIUrl":null,"url":null,"abstract":"<div><p>Immunotherapies boosting the immune system's ability to target cancer cells are promising for the treatment of various tumor types, yet clinical responses differ among patients and cancers. Recently, there has been increasing interest in novel cancer immunotherapy practices aimed at triggering T cell-mediated anti-tumor responses. Antigen-directed cytotoxicity mediated by T lymphocytes has become a central focal point in the battle against cancer utilizing the immune system. The molecular and cellular mechanisms involved in the actions of T lymphocytes have directed new therapeutic approaches in cancer immunotherapy, including checkpoint blockade, adoptive and chimeric antigen receptor (CAR) T cell therapy, and cancer vaccinology. This review addresses all the strategies targeting tumor pathogenesis, including metabolic pathways, to evaluate the clinical significance of current and future immunotherapies for patients with cancer, which are further engaged in T cell activation, differentiation, and response against tumors.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer pathogenesis and therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949713222000155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Immunotherapies boosting the immune system's ability to target cancer cells are promising for the treatment of various tumor types, yet clinical responses differ among patients and cancers. Recently, there has been increasing interest in novel cancer immunotherapy practices aimed at triggering T cell-mediated anti-tumor responses. Antigen-directed cytotoxicity mediated by T lymphocytes has become a central focal point in the battle against cancer utilizing the immune system. The molecular and cellular mechanisms involved in the actions of T lymphocytes have directed new therapeutic approaches in cancer immunotherapy, including checkpoint blockade, adoptive and chimeric antigen receptor (CAR) T cell therapy, and cancer vaccinology. This review addresses all the strategies targeting tumor pathogenesis, including metabolic pathways, to evaluate the clinical significance of current and future immunotherapies for patients with cancer, which are further engaged in T cell activation, differentiation, and response against tumors.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

T细胞在癌症免疫治疗中的作用:机遇与挑战

增强免疫系统靶向癌症细胞能力的免疫疗法有望用于治疗各种肿瘤类型，但患者和癌症的临床反应不同。最近，人们对旨在触发T细胞介导的抗肿瘤反应的新型癌症免疫疗法越来越感兴趣。T淋巴细胞介导的抗原导向细胞毒性已成为利用免疫系统对抗癌症的中心焦点。参与T淋巴细胞作用的分子和细胞机制为癌症免疫疗法提供了新的治疗方法，包括检查点阻断、过继和嵌合抗原受体（CAR）T细胞治疗以及癌症疫苗学。这篇综述涉及所有针对肿瘤发病机制的策略，包括代谢途径，以评估当前和未来免疫疗法对癌症患者的临床意义，这些疗法进一步参与T细胞激活、分化和对肿瘤的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊